首页> 外文期刊>Chemotherapy Research and Practice >Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
【24h】

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

机译:解读胰岛素样生长因子-I受体在曲妥珠单抗中的作用

获取原文
           

摘要

Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in the treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling of the insulin-like growth factor-I receptor (IGF-IR) has been reported in a subset of cell lines and clinical samples derived from trastuzumab-resistant breast cancers. Genetic and pharmacologic inhibition of IGF-IR signaling has been shown to improve response to trastuzumab in trastuzumab-naïve and trastuzumab-resistant models. In this paper, we will discuss the role of IGF-IR signaling in trastuzumab resistance. Further, we will discuss cotargeting IGF-IR and HER2 as a potential therapeutic strategy for HER2-over-expressing breast cancers that have progressed on trastuzumab treatment.
机译:对靶向HER2的抗体曲妥珠单抗的耐药性是治疗HER2过表达的转移性乳腺癌的主要临床关注点。胰岛素样生长因子-I受体(IGF-1R)的表达或信号转导已在抗曲妥珠单抗的乳腺癌细胞系和临床样品中得到了报道。在未经曲妥珠单抗和曲妥珠单抗的模型中,IGF-1R信号的遗传和药理抑制作用已显示可改善对曲妥珠单抗的反应。在本文中,我们将讨论IGF-1R信号在曲妥珠单抗耐药中的作用。此外,我们将讨论共同靶向IGF-1R和HER2作为在曲妥珠单抗治疗上取得进展的HER2过表达乳腺癌的潜在治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号